These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 7669578)
1. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Suzuki S; Uno S; Fukuda Y; Aoki Y; Masuko T; Hashimoto Y Br J Cancer; 1995 Sep; 72(3):663-8. PubMed ID: 7669578 [TBL] [Abstract][Full Text] [Related]
2. Endocytosis does not necessarily augment the cytotoxicity of adriamycin encapsulated in immunoliposomes. Suzuki S; Watanabe S; Uno S; Tanaka M; Masuko T; Hashimoto Y Biochim Biophys Acta; 1994 Dec; 1224(3):445-53. PubMed ID: 7803502 [TBL] [Abstract][Full Text] [Related]
3. In vitro targeting and cytotoxicity of adriamycin in liposomes bearing monoclonal antibody against rat or human gp125 cell proliferation-associated antigen. Tanaka T; Suzuki S; Masuko T; Hashimoto Y Jpn J Cancer Res; 1989 Apr; 80(4):380-6. PubMed ID: 2501255 [TBL] [Abstract][Full Text] [Related]
4. Immunoselective cell growth inhibition by antibody-adriamycin conjugates targeting c-erbB-2 product on human cancer cells. Suzuki S; Tanaka M; Masuko T; Hashimoto Y Biol Pharm Bull; 1995 Sep; 18(9):1279-82. PubMed ID: 8845823 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Lopes de Menezes DE; Pilarski LM; Allen TM Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662 [TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies. Ohta S; Igarashi S; Honda A; Sato S; Hanai N Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645 [TBL] [Abstract][Full Text] [Related]
7. Development of anti-p185HER2 immunoliposomes for cancer therapy. Park JW; Hong K; Carter P; Asgari H; Guo LY; Keller GA; Wirth C; Shalaby R; Kotts C; Wood WI Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1327-31. PubMed ID: 7877976 [TBL] [Abstract][Full Text] [Related]
8. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
9. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells. Li T; Amari T; Semba K; Yamamoto T; Takeoka S Nanomedicine; 2017 Apr; 13(3):1219-1227. PubMed ID: 27965166 [TBL] [Abstract][Full Text] [Related]
10. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Nam SM; Kim HS; Ahn WS; Park YS Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027 [TBL] [Abstract][Full Text] [Related]
11. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Lundberg BB; Griffiths G; Hansen HJ Int J Pharm; 2000 Sep; 205(1-2):101-8. PubMed ID: 11000546 [TBL] [Abstract][Full Text] [Related]
12. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Hancock MC; Langton BC; Chan T; Toy P; Monahan JJ; Mischak RP; Shawver LK Cancer Res; 1991 Sep; 51(17):4575-80. PubMed ID: 1678683 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Nielsen UB; Kirpotin DB; Pickering EM; Hong K; Park JW; Refaat Shalaby M; Shao Y; Benz CC; Marks JD Biochim Biophys Acta; 2002 Aug; 1591(1-3):109-118. PubMed ID: 12183061 [TBL] [Abstract][Full Text] [Related]
14. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648 [TBL] [Abstract][Full Text] [Related]
15. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788 [TBL] [Abstract][Full Text] [Related]
17. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394 [TBL] [Abstract][Full Text] [Related]
18. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Tseng YL; Hong RL; Tao MH; Chang FH Int J Cancer; 1999 Mar; 80(5):723-30. PubMed ID: 10048974 [TBL] [Abstract][Full Text] [Related]
20. Anti-laminin receptor antibody targeting of liposomes with encapsulated doxorubicin to human breast cancer cells in vitro. Rahman A; Panneerselvam M; Guirguis R; Castronovo V; Sobel ME; Abraham K; Daddona PE; Liotta LA J Natl Cancer Inst; 1989 Dec; 81(23):1794-800. PubMed ID: 2531230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]